Bio-inspired cisplatin nanocarriers for osteosarcoma treatment

Area of Science:

• Biomaterials Science
• Nanomedicine
• Oncology

Background:

• Osteosarcoma treatment often faces challenges with conventional chemotherapy drugs like cisplatin (CDDP).
• Developing effective drug delivery systems is crucial to enhance CDDP's therapeutic index.
• Surface modification of nanocarriers can improve drug targeting and reduce systemic toxicity.

Purpose of the Study:

• To develop and characterize cisplatin (CDDP) nanocarriers with phosphorylcholine surface tailoring for osteosarcoma treatment.
• To evaluate the anti-tumor efficacy and safety profile of these novel CDDP-loaded micelles.

Main Methods:

• Synthesis of poly(2-methacryloyloxyethyl phosphorylcholine)-b-poly(methacrylic acid) (PMPC-b-PMAA) copolymer.
• Preparation and characterization of CDDP/PMPC-b-PMAA micelles, including in vitro drug release studies.
• In vitro cytotoxicity assays using Saos-2 osteosarcoma cells and in vivo studies in animal models.

Main Results:

• CDDP/PMPC-b-PMAA micelles demonstrated effective self-assembly and controlled in vitro drug release.
• In vitro studies showed significant inhibition of Saos-2 cell proliferation by the micelles.
• In vivo experiments revealed prolonged circulation, reduced kidney accumulation, and enhanced tumor accumulation of CDDP/PMPC-b-PMAA micelles compared to free CDDP.

Conclusions:

• Phosphorylcholine-tailored CDDP nanocarriers (CDDP/PMPC-b-PMAA micelles) are a promising strategy for osteosarcoma therapy.
• These nanocarriers offer improved pharmacokinetic profiles and enhanced anti-tumor activity with reduced side effects.
• The developed system represents an advancement in targeted drug delivery for osteosarcoma treatment.